← Home / Opus Genetics, Inc. (IRD)
Stock Analysis
Opus Genetics, Inc. (IRD)
IRD
IRD · Market data
3.71 -3.39%
Track IRD in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IRD price is:
52W Range Position
57%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-02 12:43 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 3.84. Holding above 3.49 keeps the current thesis intact.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
3.49
↗
Break Above
Confirmation improves above resistance.
3.84
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 3.49
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
12
●
Financial Results
HIGH
Opus Genetics Announces Financial Results for
(Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate upd...
8-K Filing • SEC EDGAR
What's Driving IRD?
📈 Technical recovery is improving
Momentum is Neutral. Watch 3.84 for confirmation and 3.49 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 3.49
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
52.6
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 3.49 and resistance at 3.84. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis.
Price Chart
IRD — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Classic valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$264.9M
Company size
P/E
-5.3
Not meaningful
P/S
22.1
Very high
P/B
-5.8
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
2.16M
↘ Weak
📈 Net Income
-65.53M
↘ Negative
🧮 EPS (Basic)
-0.75
↘ Negative
Opus Genetics, Inc.
Related Opportunities